0001662579-24-000026.txt : 20240308
0001662579-24-000026.hdr.sgml : 20240308
20240308192158
ACCESSION NUMBER: 0001662579-24-000026
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240307
FILED AS OF DATE: 20240308
DATE AS OF CHANGE: 20240308
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Adams Kendra
CENTRAL INDEX KEY: 0001991929
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39567
FILM NUMBER: 24736191
MAIL ADDRESS:
STREET 1: C4 THERAPEUTICS, INC.
STREET 2: 490 ARSENAL WAY, SUITE 120
CITY: WATERTOWN
STATE: MA
ZIP: 02472
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: C4 Therapeutics, Inc.
CENTRAL INDEX KEY: 0001662579
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 475617627
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 490 ARSENAL WAY
STREET 2: SUITE 120
CITY: WATERTOWN
STATE: MA
ZIP: 02472
BUSINESS PHONE: (617) 231-0700
MAIL ADDRESS:
STREET 1: 490 ARSENAL WAY
STREET 2: SUITE 120
CITY: WATERTOWN
STATE: MA
ZIP: 02472
4
1
wk-form4_1709943708.xml
FORM 4
X0508
4
2024-03-07
0
0001662579
C4 Therapeutics, Inc.
CCCC
0001991929
Adams Kendra
C/O C4 THERAPEUTICS, INC.
490 ARSENAL WAY #120
WATERTOWN
MA
02472
0
1
0
0
Chief Financial Officer
0
Stock Option (Right to Buy)
22.71
2024-03-07
4
D
0
45000
0
D
2032-02-13
Common Stock
45000
0
D
Stock Option (Right to Buy)
19
2024-03-07
4
A
0
45000
0
A
2032-02-13
Common Stock
45000
45000
D
On March 7, 2024, the Compensation Committee of the Issuer's Board of Directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
This option vests and becomes exercisable in sixteen equal quarterly installments, with the first installment vested on May 14, 2022, subject to the Reporting Person's continued service on each vesting date.
/s/ Jolie M. Siegel, Attorney-in-Fact
2024-03-08